NuVasive Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $39.75
- Today's High:
- $39.75
- Open Price:
- $39.75
- 52W Low:
- $35.17
- 52W High:
- $49.53
- Prev. Close:
- $39.75
- Volume:
- 0
Company Statistics
- Market Cap.:
- $2.08 billion
- Book Value:
- 17.017
- Revenue TTM:
- $1.23 billion
- Operating Margin TTM:
- 6.73%
- Gross Profit TTM:
- $865.44 million
- Profit Margin:
- 2.32%
- Return on Assets TTM:
- 2.42%
- Return on Equity TTM:
- 3.31%
Company Profile
NuVasive Inc had its IPO on 2004-05-13 under the ticker symbol NUVA.
The company operates in the Healthcare sector and Medical Devices industry. NuVasive Inc has a staff strength of 3,000 employees.
Stock update
Shares of NuVasive Inc opened at $39.75 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $39.75 - $39.75, and closed at $39.75.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of NuVasive Inc have slipped by -2.24%.
NuVasive Inc's Key Ratios
NuVasive Inc has a market cap of $2.08 billion, indicating a price to book ratio of 2.615 and a price to sales ratio of 1.7925.
In the last 12-months NuVasive Inc’s revenue was $1.23 billion with a gross profit of $865.44 million and an EBITDA of $210.39 million. The EBITDA ratio measures NuVasive Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NuVasive Inc’s operating margin was 6.73% while its return on assets stood at 2.42% with a return of equity of 3.31%.
In Q2, NuVasive Inc’s quarterly earnings growth was a negative -94% while revenue growth was a positive 2.4%.
NuVasive Inc’s PE and PEG Ratio
- Forward PE
- 17.6991
- Trailing PE
- 75
- PEG
- 4.8341
Its diluted EPS in the last 12-months stands at $0.53 per share while it has a forward price to earnings multiple of 17.6991 and a PEG multiple of 4.8341. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NuVasive Inc’s profitability.
NuVasive Inc stock is trading at a EV to sales ratio of 2.4561 and a EV to EBITDA ratio of 19.3981. Its price to sales ratio in the trailing 12-months stood at 1.7925.
NuVasive Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.09 billion
- Total Liabilities
- $582.58 million
- Operating Cash Flow
- $-40094000.00
- Capital Expenditure
- $37.01 million
- Dividend Payout Ratio
- 0%
NuVasive Inc ended 2024 with $2.09 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.09 billion while shareholder equity stood at $892.54 million.
NuVasive Inc ended 2024 with $15.98 million in deferred long-term liabilities, $582.58 million in other current liabilities, 63000.00 in common stock, $92.47 million in retained earnings and $638.43 million in goodwill. Its cash balance stood at $80.72 million and cash and short-term investments were $80.72 million. The company’s total short-term debt was $360,785,000 while long-term debt stood at $445.54 million.
NuVasive Inc’s total current assets stands at $728.25 million while long-term investments were $0 and short-term investments were $1.49 million. Its net receivables were $267.11 million compared to accounts payable of $118.81 million and inventory worth $350.81 million.
In 2024, NuVasive Inc's operating cash flow was $-40094000.00 while its capital expenditure stood at $37.01 million.
Comparatively, NuVasive Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $39.75
- 52-Week High
- $49.53
- 52-Week Low
- $35.17
- Analyst Target Price
- $49.73
NuVasive Inc stock is currently trading at $39.75 per share. It touched a 52-week high of $49.53 and a 52-week low of $49.53. Analysts tracking the stock have a 12-month average target price of $49.73.
Its 50-day moving average was $40.72 and 200-day moving average was $41.31 The short ratio stood at 10.29 indicating a short percent outstanding of 0%.
Around 27.3% of the company’s stock are held by insiders while 10477.8% are held by institutions.
Frequently Asked Questions About NuVasive Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.